

## Olivier Peyr : contributeur et auteur dans la recherche

1. Richette, P. *et al.* Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. *Annals of the Rheumatic Diseases* 80, 349–355 (2021).
2. Jacquier, H. *et al.* Benefits of Polymerase Chain Reaction Combined With Culture for the Diagnosis of Bone and Joint Infections: A Prospective Test Performance Study. *Open Forum Infectious Diseases* 6, ofz511 (2019).
3. Henrotin, Y. *et al.* Hyaluronan derivative HYMOVIS® increases cartilage volume and Type II collagen turnover in osteoarthritic knee: data from MOKHA study. *BMC Musculoskelet Disord* 20, 293 (2019).
4. Ebstein, E. *et al.* Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. *Rheumatology* 58, 410–417 (2019).
5. Vanier, A., Mariette, X., Tubach, F. & Fautrel, B. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial. *Value in Health* 20, 577–585 (2017).
6. Dougados, M. *et al.* Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. *Ann. Rheum. Dis.* (2017) doi:10.1136/annrheumdis-2017-211596.
7. Taylor, W. J. *et al.* Performance of classification criteria for gout in early and established disease. *Ann Rheum Dis* 75, 178–182 (2016).
8. Gottenberg, J.-E. *et al.* Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. *JAMA* 316, 1172–1180 (2016).
9. Frazier-Mironer, A. *et al.* Efficacité de l'éducation thérapeutique (ETP) dans la goutte : résultats sur 80 patients. *Revue du Rhumatisme* 83, A131 (2016).
10. Fautrel, B. *et al.* Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid Arthritis Study). *Ann. Rheum. Dis.* 75, 59–67 (2016).
11. Taylor, W. J. *et al.* Study for Updated Gout Classification Criteria (SUGAR): identification of features to classify gout. *Arthritis Care Res (Hoboken)* 67, 1304–1315 (2015).
12. Richette, P. *et al.* Identification of patients with gout: elaboration of a questionnaire for epidemiological studies. *Ann. Rheum. Dis.* 74, 1684–1690 (2015).
13. Jallouli, M. *et al.* Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. *Arthritis & Rheumatology (Hoboken, N.J.)* 67, 2176–2184 (2015).
14. Chevalier, X. *et al.* Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. *Ann. Rheum. Dis.* 74, 1697–1705 (2015).
15. Schoindre, Y. *et al.* Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. *Lupus Sci Med* 1, (2014).
16. Ritchlin, C. *et al.* Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Ann. Rheum. Dis.* 73, 990–999 (2014).
17. Dougados, M. *et al.* Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). *Ann. Rheum. Dis.* (2014) doi:10.1136/annrheumdis-2013-204733.
18. Richette, P. *et al.* Psoriasis and phenotype of patients with early inflammatory back pain. *Ann. Rheum. Dis.* 72, 566–571 (2013).
19. Morel, N. *et al.* Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. *J. Clin. Endocrinol. Metab.* 98, 3785–3792 (2013).
20. Jallouli, M. *et al.* Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. *JAMA Dermatol* 149, 935–940 (2013).
21. Costedoat-Chalumeau, N. *et al.* Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). *Ann. Rheum. Dis.* 72, 1786–1792 (2013).
22. Mariette, X. *et al.* Influence of replacing tuberculin skin test with ex vivo interferon  $\gamma$  release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. *Ann. Rheum. Dis.* 71, 1783–1790 (2012).